Go Pro

Stonehage Fleming Financial Services Holdings Ltd Purchases Shares of 340,263 West Pharmaceutical Services, Inc. $WST

West Pharmaceutical Services logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Stonehage Fleming Financial Services Holdings acquired 340,263 shares of West Pharmaceutical Services valued at approximately $122.2 million, representing 0.48% of WST and 4.2% of the fund’s portfolio. Institutional investors and hedge funds collectively own 93.9% of the company.
  • West Pharmaceutical Services reported quarterly EPS of $2.37, beating expectations of $2.08, while revenue rose 13.8% year over year to $872.3 million. The company forecast full-year 2026 EPS of $8.85–$9.05.
  • WST recently declared a quarterly dividend of $0.22, equivalent to an annualized $0.88 payout and a 0.3% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $368.08.
  • Five stocks we like better than West Pharmaceutical Services.

Stonehage Fleming Financial Services Holdings Ltd purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 340,263 shares of the medical instruments supplier's stock, valued at approximately $122,154,000. West Pharmaceutical Services comprises approximately 4.2% of Stonehage Fleming Financial Services Holdings Ltd's holdings, making the stock its 13th largest holding. Stonehage Fleming Financial Services Holdings Ltd owned 0.48% of West Pharmaceutical Services as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Addison Advisors LLC acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at approximately $28,000. Avalon Trust Co bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $28,000. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth $25,000. Bayban acquired a new position in West Pharmaceutical Services during the 4th quarter worth $27,000. Finally, DV Equities LLC bought a new position in shares of West Pharmaceutical Services in the fourth quarter worth $28,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Down 0.9%

Shares of West Pharmaceutical Services stock opened at $346.67 on Friday. The business has a fifty day simple moving average of $350.35 and a 200-day simple moving average of $303.37. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00. The firm has a market cap of $24.40 billion, a price-to-earnings ratio of 44.39, a price-to-earnings-growth ratio of 2.45 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $2.08 by $0.29. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business's quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services's dividend payout ratio is currently 11.27%.

Analysts Set New Price Targets

A number of brokerages have recently commented on WST. TD Cowen reissued a "buy" rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Weiss Ratings raised shares of West Pharmaceutical Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 7th. Stephens reissued an "overweight" rating and set a $360.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. KeyCorp raised their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an "overweight" rating in a research note on Thursday, July 2nd. Finally, Zacks Research downgraded shares of West Pharmaceutical Services from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $368.08.

Read Our Latest Stock Report on WST

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.

Featured Articles

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST - Free Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in West Pharmaceutical Services Right Now?

Before you consider West Pharmaceutical Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.

While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines